Organon (OGN) Aktievy
Organon & Co. utvecklar och levererar lösningar för kvinnors hälsa genom receptbelagda terapier och medicintekniska produkter i USA, Europa, Kanada, Japan, övriga Asien och Stillahavsområdet, Kina, Latinamerika, Mellanöstern, Ryssland, Afrika och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 4/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 1/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
+ 1 större risk
OGN Community Fair Values
Create NarrativeSee what 62 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Organon & Co. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$13.43 |
| 52 veckors högsta | US$13.48 |
| 52 veckors lägsta | US$5.69 |
| Beta | 1.55 |
| 1 månads förändring | 46.94% |
| 3 månaders förändring | 65.80% |
| 1 års förändring | 54.55% |
| 3 års förändring | -31.27% |
| 5 års förändring | -62.43% |
| Förändring sedan börsintroduktionen | -59.61% |
Senaste nyheter och uppdateringar
Recent updates
Uppdatering av berättelse • May 07
OGN: Deal Premium And Mixed Ratings Will Limit Further Upside Potential
Analysts have lifted their Organon fair value estimate from $9.00 to $11.25, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E following a mix of recent rating changes, deal interest commentary, and a revised $8.00 price target from Barclays. Analyst Commentary Recent Street research on Organon shows a split view, with some analysts highlighting potential upside drivers and others focusing on execution risks and valuation constraints.
Uppdatering av berättelse • Apr 22
OGN: Takeover Talk Will Likely Leave Shares Struggling Below Deal Level
Analysts have nudged Organon’s target higher, reflecting updated models that incorporate recent takeover interest around $15 per share and sector valuation readthroughs, along with revised assumptions for revenue growth, margins, discount rate, and future P/E. Analyst Commentary Recent research highlights a mix of interest and caution around Organon, with potential deal scenarios and updated sector comparisons feeding into valuation work.Seeking Alpha • Apr 13
Organon Takeover At $15? Probably Not, Here's Why
Summary Organon & Co. stock surged nearly 30% after a report of a $12 billion enterprise value all-cash takeover offer from Sun Pharmaceutical Industries. Analysts were quick to argue that the enterprise value could imply an equity value of $15 per share. However, based on a balance sheet deep dive detailed in this article, I will demonstrate that the consideration paid to shareholders could end up being significantly lower. At the same time, there are other arguments in favor of an enterprise valuation translating to almost $15 per share equity valuation. Following the announcement, I no longer have any interest in buying OGN shares outright, but I might consider an options-based strategy. Read the full article on Seeking AlphaUppdatering av berättelse • Apr 07
OGN: Raised Price View Will Likely Leave Shares Trapped Near Lows
Analysts have nudged their Organon price target to $8 from $7.50, reflecting updated models after the latest Q4 report and adjusted assumptions around discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent research reflects a cautious stance around Organon, even as the price target was adjusted to US$8 from US$7.50 after the latest Q4 report.Uppdatering av berättelse • Mar 24
OGN: Cautious Q4 Reassessment Will Likely Keep Shares Anchored Near Lows
Analysts have nudged their price target on Organon up to $8 from $7.50, reflecting updated models after the recent Q4 report and a fresh look at the company’s fundamentals. Analyst Commentary Bearish analysts are treating the latest price target move as a fine tuning of a cautious view rather than a shift in conviction.Uppdatering av berättelse • Mar 10
OGN: Refreshed Earnings Assumptions And M&A Interest Will Support Future Repricing
Analysts have trimmed their fair value estimate for Organon to $9.00, while Barclays lifted its price target to $8.00 from $7.50 after updating its model following the Q4 report, prompting a reassessment of growth, margins and future P/E assumptions in our narrative update. Analyst Commentary Recent Street research reflects a cautious stance on Organon, even as some price targets are adjusted following the Q4 update.
Uppdatering av berättelse • Feb 24
OGN: Potential Takeover Interest Will Drive Future Upside Opportunity
Analysts have trimmed their price target on Organon from $18.00 to $12.00, citing updated assumptions that include a revised fair value estimate, a slightly higher discount rate, a modestly adjusted revenue growth outlook, a lower projected profit margin, and a reduced future P/E multiple. What's in the News Organon issued earnings guidance for full year 2026, targeting approximately US$6.2b in revenue, giving investors a reference point for management's current expectations (Corporate guidance).Uppdatering av berättelse • Feb 10
OGN: Acquisition Interest And New Approvals Will Support A Rerated Earnings Profile
Analysts have revised their price targets on Organon. The updated view reflects changes in the discount rate, revenue growth assumptions, profit margin outlook, and future P/E expectations.Analysartikel • Jan 29
The Market Lifts Organon & Co. (NYSE:OGN) Shares 25% But It Can Do More
Organon & Co. ( NYSE:OGN ) shares have continued their recent momentum with a 25% gain in the last month alone. Not all...Uppdatering av berättelse • Jan 26
OGN: Governance Reset And Policy Headwinds Will Shape A Steady Execution Path
Narrative update on Organon Analysts have trimmed their price target on Organon to US$9 from US$10, reflecting updated views on U.S. policy headwinds for Nexplanon, recent sales practice issues limited to that product, and softer expectations in the respiratory business that also feed into slightly lower discount rate and future P/E assumptions. Analyst Commentary Recent commentary focuses on how the updated guidance and product specific issues could affect Organon’s valuation, execution risk, and medium term growth profile.Uppdatering av berättelse • Jan 11
OGN: Governance Reset Around Nexplanon Controls Will Gradually Restore Market Confidence
Analysts have trimmed their price targets on Organon, with cuts such as US$10 to US$9 and US$18 to US$5. These changes reflect ongoing concerns about the Nexplanon related investigation, recent leadership changes, and updated revenue guidance.Uppdatering av berättelse • Dec 26
OGN Internal Control Failures Will Likely Drive Shares Toward Mid Single Digits
Analysts have sharply reduced their Organon price target to about $5 from roughly $9, citing downgraded ratings and heightened concerns over internal controls, Nexplanon related channel stuffing, and softer revenue guidance, which is being weighed down by U.S. policy headwinds and respiratory portfolio challenges. Analyst Commentary Bearish analysts are signaling a more cautious stance on Organon, reflecting heightened skepticism around the company’s execution, governance, and growth outlook.Uppdatering av berättelse • Dec 12
OGN: Governance Reset And New Leadership Will Restore Confidence Over Time
Analysts trimmed their price target on Organon by about one dollar to reflect a slightly lower fair value estimate, modestly higher perceived risk, and concerns over internal control breakdowns and Nexplanon-driven revenue headwinds. Analyst Commentary Recent Street research reflects a far more cautious stance on Organon, with reduced price targets and weaker ratings signaling diminished confidence in the company’s near term execution and growth trajectory.Uppdatering av berättelse • Nov 28
OGN: Leadership Changes And Governance Reforms Will Drive Renewed Confidence
Analysts have lowered their price target for Organon and now expect $9.67 per share, compared to the prior estimate of $10.33. The change is attributed to continued headwinds from internal control concerns and weaker revenue growth forecasts.Analysartikel • Nov 14
Earnings Release: Here's Why Analysts Cut Their Organon & Co. (NYSE:OGN) Price Target To US$9.67
It's been a pretty great week for Organon & Co. ( NYSE:OGN ) shareholders, with its shares surging 14% to US$7.62 in...Uppdatering av berättelse • Nov 12
OGN: Internal Control Improvements Will Restore Confidence Amid Leadership Transition
Organon’s analyst price target was reduced from $10 to $9, as analysts cited concerns around internal controls, lowered revenue guidance, and lingering effects from recent leadership and business challenges. Analyst Commentary Recent Street research reflects a challenging outlook for Organon, with analysts closely scrutinizing both the company's fundamentals and the longer-term prospects following significant leadership changes and internal control issues.Analysartikel • Nov 06
Investors Give Organon & Co. (NYSE:OGN) Shares A 41% Hiding
Organon & Co. ( NYSE:OGN ) shareholders won't be pleased to see that the share price has had a very rough month...Uppdatering av berättelse • Oct 27
Leadership Changes And Regulatory Concerns Will Shape Near-Term Market Prospects
Organon's analyst price target has dropped sharply from $13.17 to $10.83. Analysts cite lingering concerns about internal controls and leadership stability following recent executive changes and investigations.Uppdatering av berättelse • Aug 06
New Product Launches And Biosimilars Will Open Global Healthcare Markets
Despite improved revenue growth forecasts for Organon, a higher discount rate has outweighed these gains, resulting in a lower consensus price target from $13.33 to $12.60. What's in the News Organon raised full-year 2025 revenue guidance to $6.275–$6.375 billion and slightly improved its nominal revenue growth outlook.Analysartikel • May 08
Why Investors Shouldn't Be Surprised By Organon & Co.'s (NYSE:OGN) 30% Share Price Plunge
To the annoyance of some shareholders, Organon & Co. ( NYSE:OGN ) shares are down a considerable 30% in the last month...Analysartikel • May 04
Organon's (NYSE:OGN) Dividend Is Being Reduced To $0.02
Organon & Co. ( NYSE:OGN ) is reducing its dividend from last year's comparable payment to $0.02 on the 12th of June...Analysartikel • Apr 28
Organon (NYSE:OGN) Use Of Debt Could Be Considered Risky
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Mar 24
Earnings Working Against Organon & Co.'s (NYSE:OGN) Share Price
With a price-to-earnings (or "P/E") ratio of 4.6x Organon & Co. ( NYSE:OGN ) may be sending very bullish signals at the...Seeking Alpha • Mar 18
Why Organon Is A Top Pick For Income Investors
Summary In mid-February, Organon pleasantly surprised me with its financial results for the fourth quarter of 2024. So, sales of Hadlima, a biosimilar to Humira, amounted to $44 million in the last three months of 2024, an increase of 83.3% year-on-year. Organon's dividend yield is 7.32%, which is significantly higher than that of the healthcare sector. In this article, you'll learn more about why I believe Organon is an attractive stock for income-oriented investors. Read the full article on Seeking AlphaAnalysartikel • Feb 17
Organon's (NYSE:OGN) Dividend Will Be $0.28
Organon & Co.'s ( NYSE:OGN ) investors are due to receive a payment of $0.28 per share on 13th of March. The dividend...Seeking Alpha • Jan 17
Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield
Summary Organon has faced significant price volatility and underperformance since its spin-off from Merck, with shares down ~50% since 2021. Key products like Nexplanon and VTAMA are crucial for future growth, but uncertainties and competition pose significant risks to revenue projections. Organon's high debt and interest payments are significant concerns, despite low P/S and P/E ratios suggesting undervaluation, and a strong dividend yield. I recommend a "Hold" for 2025, focusing on collecting dividends and avoiding the downside, with the potential for improved performance in 18–24 months. Read the full article on Seeking AlphaAktieägarnas avkastning
| OGN | US Pharmaceuticals | US Marknad | |
|---|---|---|---|
| 7D | 0.2% | 4.9% | 1.0% |
| 1Y | 54.5% | 44.2% | 28.7% |
Avkastning vs industri: OGN översteg US Pharmaceuticals branschen som gav 44.2 % under det senaste året.
Avkastning vs Marknaden: OGN översteg US marknaden som gav 28.7 % under det senaste året.
Prisvolatilitet
| OGN volatility | |
|---|---|
| OGN Average Weekly Movement | 14.6% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: OGN s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: OGN s veckovolatilitet ( 15% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av US aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1923 | 10,000 | Joe Morrissey | www.organon.com |
Organon & Co. utvecklar och levererar lösningar för kvinnors hälsa genom receptbelagda läkemedel och medicintekniska produkter i USA, Europa, Kanada, Japan, övriga Asien och Stillahavsområdet, Kina, Latinamerika, Mellanöstern, Ryssland, Afrika och internationellt. Bolagets produktportfölj inom kvinnohälsa omfattar varumärken inom preventivmedel och fertilitet, t ex Nexplanon, ett långtidsverkande reversibelt preventivmedel, NuvaRing, en vaginal preventivring som används en gång i månaden, Cerazette, Marvelon och Mercilon för att förhindra graviditet; Follistim AQ, som används för att främja utvecklingen av äggstocksfolliklar; Elonva, en follikelstimulerande substans; Ganirelixacetatinjektion, en injicerbar antagonist; Jada för onormal livmoderblödning och blödning efter förlossningen; och Xaciato för bakteriell vaginos. Bolagets portfölj av biosimilarer består av immunologiprodukter som Brenzys, Renflexis och Hadlima, onkologiprodukter som Ontruzant och Aybintio, Bildyos och Bilprevda, rekombinanta humana monoklonala antikroppar mot RANKL, samt Poherdy, en neu-receptorantagonist.
Organon & Co. Sammanfattning av grunderna
| OGN grundläggande statistik | |
|---|---|
| Börsvärde | US$3.52b |
| Vinst(TTM) | US$246.00m |
| Intäkter(TTM) | US$6.16b |
14.3x
P/E-förhållande0.6x
P/S-förhållandeÄr OGN övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| OGN resultaträkning (TTM) | |
|---|---|
| Intäkter | US$6.16b |
| Kostnad för intäkter | US$2.85b |
| Bruttovinst | US$3.32b |
| Övriga kostnader | US$3.07b |
| Intäkter | US$246.00m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 0.94 |
| Bruttomarginal | 53.84% |
| Nettovinstmarginal | 3.99% |
| Skuld/egenkapitalförhållande | 948.9% |
Hur har OGN utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
0.6%
Aktuell utdelningsavkastning8%
UtbetalningskvotGer OGN en tillförlitlig utdelning?
Se OGN utdelningshistorik och jämförelsetal| Organon datum för utdelning | |
|---|---|
| Ex utdelningsdag | May 11 2026 |
| Utbetalningsdag för utdelning | Jun 11 2026 |
| Dagar till Ex-utdelning | 13 days |
| Dagar till utdelningsdag | 18 days |
Ger OGN en tillförlitlig utdelning?
Se OGN utdelningshistorik och jämförelsetalFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/22 15:08 |
| Aktiekurs vid dagens slut | 2026/05/22 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Organon & Co. bevakas av 14 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Glen Santangelo | Barclays |
| Navann Ty Dietschi | BNP Paribas |
| Jason Matthew Gerberry | BofA Global Research |